Suchergebnisse - "Denosumab adverse effects"

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

Autoren: J. Lane B. Langdahl M. Stone et al.

Quelle: Osteoporos Int
Lane, J, Langdahl, B, Stone, M, Kurth, A, Oates, M, Timoshanko, J, Wang, Z, Libanati, C & Cosman, F 2024, 'Romosozumab in patients who experienced an on-study fracture : post hoc analyses of the FRAME and ARCH phase 3 trials', Osteoporosis International, vol. 35, no. 7, pp. 1195-1204. https://doi.org/10.1007/s00198-024-07049-w

Schlagwörter: Aged, 80 and over, Bone Density Conservation Agents, Alendronate, Fracture risk, Antibodies, Monoclonal, Middle Aged, On-study fracture, Drug Administration Schedule, 3. Good health, Double-Blind Method, Bone Density, Recurrence, Romosozumab, Bone mineral density, Osteoporosis, Humans, Spinal Fractures, Original Article, Female, Denosumab, Osteoporotic Fractures, Osteoporosis, Postmenopausal, Double-Blind Method [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Antibodies, Monoclonal/therapeutic use [MeSH], Osteoporosis, Postmenopausal/complications [MeSH], Alendronate/adverse effects [MeSH], Osteoporosis, Postmenopausal/drug therapy [MeSH], Alendronate/administration, Osteoporosis, Postmenopausal/physiopathology [MeSH], Bone Density Conservation Agents/therapeutic use [MeSH], Antibodies, Monoclonal/administration, Alendronate/therapeutic use [MeSH], Female [MeSH], Bone Density Conservation Agents/administration, Bone Density/drug effects [MeSH], Humans [MeSH], Spinal Fractures/physiopathology [MeSH], Spinal Fractures/prevention, Drug Administration Schedule [MeSH], Middle Aged [MeSH], Denosumab/administration, Osteoporotic Fractures/prevention, Denosumab/therapeutic use [MeSH], Recurrence [MeSH], Bone Density Conservation Agents/adverse effects [MeSH], Denosumab/adverse effects [MeSH], Antibodies, Monoclonal/adverse effects [MeSH], Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38573517
https://repository.publisso.de/resource/frl:6517887
https://pure.au.dk/portal/en/publications/d5c2d2f1-6dd9-4508-8459-0e76fbe09ba4
http://www.scopus.com/inward/record.url?scp=85189426658&partnerID=8YFLogxK
https://doi.org/10.1007/s00198-024-07049-w

Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach

Autoren: Olivier Lamy Judith Everts-Graber Elena Gonzalez Rodriguez

Quelle: Aging Clin Exp Res
Aging clinical and experimental research, vol. 37, no. 1, pp. 70

Schlagwörter: Humans, Denosumab/therapeutic use, Denosumab/adverse effects, Denosumab/administration & dosage, Bone Density Conservation Agents/therapeutic use, Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/administration & dosage, Osteoporosis/drug therapy, Female, Bone Density/drug effects, Diphosphonates/therapeutic use, Denosumab, Fracture, Multiple vertebral fractures, Osteoporosis, Rebound effect, Bone Density Conservation Agents, Diphosphonates, Bone Density, Review

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40055268
https://serval.unil.ch/notice/serval:BIB_E4C8D530B910
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_E4C8D530B9107
https://serval.unil.ch/resource/serval:BIB_E4C8D530B910.P001/REF.pdf

Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document

Autoren: Joel A Vanderniet Vivian Szymczuk Wolfgang Högler et al.

Quelle: J Clin Endocrinol Metab
Vanderniet, J A, Szymczuk, V, Högler, W, Beck-Nielsen, S S, Uday, S, Merchant, N, Crane, J L, Ward, L M, Boyce, A M & Munns, C F 2024, 'Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents : A Global Expert Guidance Document', The Journal of clinical endocrinology and metabolism, vol. 109, no. 5, pp. 1371-1382. https://doi.org/10.1210/clinem/dgad657

Schlagwörter: Minerals, Adolescent, Bone Density Conservation Agents, rebound hypercalcemia, Reports and Recommendations, fibrous dysplasia, RANK Ligand, hypocalcemia, Ligands, 16. Peace & justice, Bone and Bones, 3. Good health, aneurysmal bone cyst, Humans, Bone Density Conservation Agents/adverse effects, Denosumab, bone mineral density, Denosumab/adverse effects, Child, giant cell tumor

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38041865
https://pure.au.dk/portal/en/publications/84e630f1-7fbc-4ef9-8b4d-f4775211c003
https://doi.org/10.1210/clinem/dgad657
http://www.scopus.com/inward/record.url?scp=85191102115&partnerID=8YFLogxK

Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone

Autoren: Ferrari, Serge Livio Langdahl, Bente

Quelle: Ferrari, S & Langdahl, B 2023, 'Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone', Nature Reviews Rheumatology, vol. 19, no. 5, pp. 307-317. https://doi.org/10.1038/s41584-023-00935-3

Schlagwörter: Bone Density Conservation Agents, RANK Ligand, Antibodies, Monoclonal, Humanized / adverse effects, Osteoporosis / chemically induced, Antibodies, Monoclonal, Osteoclasts, Bone Density Conservation Agents / adverse effects, RANK Ligand / therapeutic use, Antibodies, Monoclonal, Humanized, Bone and Bones, 3. Good health, Antibodies, Monoclonal / therapeutic use, Osteoporosis / drug therapy, Bone Density, RANK Ligand / pharmacology, Humans, Osteoporosis, Denosumab, Denosumab / adverse effects

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37024711
https://archive-ouverte.unige.ch/unige:176395
https://doi.org/10.1038/s41584-023-00935-3
https://pure.au.dk/portal/en/publications/6e355038-471e-4337-b1e6-441b75207f63
https://doi.org/10.1038/s41584-023-00935-3
http://www.scopus.com/inward/record.url?scp=85152083828&partnerID=8YFLogxK

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

Autoren: Langdahl, Bente Hofbauer, Lorenz C. Ferrari, Serge et al.

Quelle: Osteoporos Int
Langdahl, B, Hofbauer, L C, Ferrari, S, Wang, Z, Fahrleitner-Pammer, A, Gielen, E, Lakatos, P, Czerwinski, E, Gimeno, E J, Timoshanko, J, Oates, M & Libanati, C 2022, 'Romosozumab efficacy and safety in European patients enrolled in the FRAME trial', Osteoporosis International, vol. 33, no. 12, pp. 2527-2536. https://doi.org/10.1007/s00198-022-06544-2

Schlagwörter: 0301 basic medicine, META-REGRESSION, FRACTURE RISK, 4202 Epidemiology, Bone Density Conservation Agents / adverse effects, OSTEOPOROSIS, 1117 Public Health and Health Services, 12. Responsible consumption, Osteoporotic Fractures/chemically induced, Endocrinology & Metabolism, 03 medical and health sciences, Clinical trials, 0302 clinical medicine, 0903 Biomedical Engineering, Double-Blind Method, Osteoporosis, Postmenopausal/complications, Bone Density, Humans, Bone Density Conservation Agents/adverse effects, Denosumab/adverse effects, Anabolics, Osteoporosis, Postmenopausal, Denosumab / adverse effects, Science & Technology, Bone Density Conservation Agents, Osteoporosis, Postmenopausal / complications, 3202 Clinical sciences, HIP FRACTURE, 1103 Clinical Sciences, 3. Good health, REDUCTION, POSTMENOPAUSAL WOMEN, Clinical fractures, Osteoporosis, Original Article, Female, Osteoporotic Fractures / chemically induced, BONE-MINERAL DENSITY, Denosumab, Life Sciences & Biomedicine, Osteoporotic Fractures

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36173415
https://lirias.kuleuven.be/handle/20.500.12942/703647
https://doi.org/10.1007/s00198-022-06544-2
https://pure.au.dk/portal/en/publications/459a979d-5aea-42a7-bf02-f8da69a6d509
https://pure.au.dk/portal/en/publications/459a979d-5aea-42a7-bf02-f8da69a6d509
https://doi.org/10.1007/s00198-022-06544-2
https://pure.au.dk/ws/files/347114418/s00198-022-06544-2.pdf

Discontinuation of denosumab in men with prostate cancer

Autoren: Anne Sophie Sølling Torben Harsløf Helle Kongsbak Brockstedt et al.

Quelle: Sølling, A S, Harsløf, T, Brockstedt, H K & Langdahl, B L 2023, 'Discontinuation of denosumab in men with prostate cancer', Osteoporosis International, vol. 34, no. 2, pp. 291-297. https://doi.org/10.1007/s00198-022-06610-9

Schlagwörter: Prostatic Neoplasms/complications, Male, 0301 basic medicine, 0303 health sciences, Prostate cancer, Bone Density Conservation Agents, Prostatic Neoplasms, Androgen Antagonists, Zoledronic Acid, Zoledronic Acid/therapeutic use, 3. Good health, Bone Diseases, Metabolic, 03 medical and health sciences, Bone Density, Bone mineral density, Androgens, Osteoporosis, Humans, Bone Density Conservation Agents/adverse effects, Denosumab, Denosumab/adverse effects, Androgen Antagonists/adverse effects, Bone Diseases, Metabolic/chemically induced, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36402867
http://www.scopus.com/inward/record.url?scp=85142239370&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/70ef8cee-6563-483a-ace1-70eac0d13ab7
https://doi.org/10.1007/s00198-022-06610-9

Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea

Autoren: Yumie Rhee Dong-Gune Chang Jeonghoon Ha et al.

Weitere Verfasser: Yumie Rhee Dong-Gune Chang Jeonghoon Ha et al.

Quelle: Endocrinol Metab (Seoul)
Endocrinology and Metabolism, Vol 37, Iss 3, Pp 497-505 (2022)

Schlagwörter: safety, Male, Bone Density Conservation Agents* / adverse effects, Osteoporosis* / chemically induced, Postmenopausal* / drug therapy, korea, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, 0302 clinical medicine, Postmarketing drug surveillance, Humans, Prospective Studies, Postmenopausal* / chemically induced, Osteoporosis, Postmenopausal, Denosumab / adverse effects, Aged, Korea, Bone Density Conservation Agents, bone density, Postmenopausal* / complications, denosumab, Middle Aged, RC648-665, osteoporosis, postmarketing drug surveillance, 3. Good health, Osteoporosis* / drug therapy, Osteoporosis, Original Article, Female, Safety, Denosumab, Bone density

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35654577
https://doaj.org/article/d5b8568c8cbf484d94719850ef9c7fd6

Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab

Autoren: Alexander Wick Philipp Bankosegger Sven Otto et al.

Quelle: Clin Oral Investig
Clinical oral investigations 26(3), 2839-2852 (2022). doi:10.1007/s00784-021-04261-4

Schlagwörter: 03 medical and health sciences, Original Article, Osteonecrosis of the jaw, Bone Density Conservation Agents/adverse effects [MeSH], Humans [MeSH], Denosumab, Denosumab/adverse effects [MeSH], Retrospective Studies [MeSH], MRONJ, Risk Factors [MeSH], Bisphosphonates, Risk factors, Bisphosphonate-Associated Osteonecrosis of the Jaw/prevention, 0302 clinical medicine, Bone Density Conservation Agents, Risk Factors, Humans, Bisphosphonate-Associated Osteonecrosis of the Jaw, Retrospective Studies, 3. Good health

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00784-021-04261-4.pdf
https://pubmed.ncbi.nlm.nih.gov/34812959
https://www.ncbi.nlm.nih.gov/pubmed/34812959
https://link.springer.com/content/pdf/10.1007/s00784-021-04261-4.pdf
https://repository.publisso.de/resource/frl:6449130
https://epub.ub.uni-muenchen.de/90882/
https://publications.rwth-aachen.de/record/852034

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

Autoren: Peter Burckhardt Mohamed Faouzi Thierry Buclin et al.

Weitere Verfasser: Peter Burckhardt Mohamed Faouzi Thierry Buclin et al.

Quelle: J Bone Miner Res
Journal of bone and mineral research, vol. 36, no. 9, pp. 1717-1728

Schlagwörter: Fractures, Bone, 03 medical and health sciences, 0302 clinical medicine, Bone Density Conservation Agents, Diphosphonates, Bone Density, Humans, Original Articles, Denosumab/adverse effects, Diphosphonates/adverse effects, Retrospective Studies, ANTIRESORPTIVES, DENOSUMAB, FRACTURE RISK ASSESSMENT, OSTEOPOROSIS, STATISTICAL METHODS, Denosumab, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jbmr.4335
https://pubmed.ncbi.nlm.nih.gov/34009703
https://pubmed.ncbi.nlm.nih.gov/34009703/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518625/
https://asbmr.onlinelibrary.wiley.com/doi/full/10.1002/jbmr.4335
https://europepmc.org/article/MED/34009703
https://serval.unil.ch/notice/serval:BIB_3B3FDC4DE2B9
https://serval.unil.ch/resource/serval:BIB_3B3FDC4DE2B9.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_3B3FDC4DE2B93

Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?

Autoren: Sydlik, Carmen Dürr, Hans Roland Bechtold-Dalla Pozza, Susanne et al.

Quelle: World J Pediatr

Schlagwörter: Giant Cell Tumor of Bone, Male, Adolescent, Diphosphonates, Brief Report, Diphosphonates/adverse effects [MeSH], Adolescent [MeSH], Female [MeSH], Giant cell tumor of the bone, Giant Cell Tumor of Bone/drug therapy [MeSH], Humans [MeSH], Bone Cysts, Aneurysmal/drug therapy [MeSH], Male [MeSH], Aneurysmatic bone cyst, Hypercalcemia/chemically induced [MeSH], Denosumab, Denosumab/adverse effects [MeSH], Bisphosphonates, Calcium homeostasis, Child [MeSH], 3. Good health, Bone Cysts, Aneurysmal, 03 medical and health sciences, 0302 clinical medicine, Hypercalcemia, Humans, Female, Child

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s12519-020-00378-w.pdf
https://pubmed.ncbi.nlm.nih.gov/32776272
https://link.springer.com/content/pdf/10.1007/s12519-020-00378-w.pdf
https://link.springer.com/article/10.1007/s12519-020-00378-w
https://www.ncbi.nlm.nih.gov/pubmed/32776272
https://paperity.org/p/256023730/hypercalcaemia-after-treatment-with-denosumab-in-children-bisphosphonates-as-an-option
https://epub.ub.uni-muenchen.de/73144/
https://pubmed.ncbi.nlm.nih.gov/32776272/
https://repository.publisso.de/resource/frl:6471940
https://epub.ub.uni-muenchen.de/73144/

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women : systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

Autoren: Händel, Mina Nicole Cardoso, Isabel von Bülow, Cecilie et al.

Quelle: ISSN: 1756-1833 ; BMJ, vol. 381 (2023) e068033.

Schlagwörter: info:eu-repo/classification/ddc/616, Humans, Female, Bone Density Conservation Agents / adverse effects, Network Meta-Analysis, Postmenopause, Denosumab / adverse effects, Receptor, Parathyroid Hormone, Type 1, Osteoporosis / drug therapy, Osteoporotic Fractures / prevention & control, Diphosphonates / adverse effects, Spinal Fractures, Risk Reduction Behavior, Osteoporosis, Postmenopausal / complications, Postmenopausal / drug therapy, Randomized Controlled Trials as Topic

Relation: info:eu-repo/semantics/altIdentifier/pmid/37130601; unige:176377

Verfügbarkeit: https://archive-ouverte.unige.ch/unige:176377

Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women:systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials

Autoren: Händel, Mina Nicole Cardoso, Isabel Von Bülow, Cecilie et al.

Quelle: Händel, M N, Cardoso, I, Von Bülow, C, Rohde, J F, Ussing, A, Nielsen, S M, Christensen, R, Body, J J, Brandi, M L, Diez-Perez, A, Hadji, P, Javaid, M K, Lems, W F, Nogues, X, Roux, C, Minisola, S, Kurth, A, Thomas, T, Prieto-Alhambra, D, Ferrari, S L, Langdahl, B & Abrahamsen, B 2023, 'Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women : systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials', BMJ, vol. 381, e068033. https://doi.org/10.1136/bmj-2021-068033

Schlagwörter: Bone Density Conservation Agents/adverse effects, Denosumab/adverse effects, Diphosphonates/adverse effects, Female, Humans, Network Meta-Analysis, Osteoporosis, Postmenopausal/complications, Osteoporosis/drug therapy, Osteoporotic Fractures/prevention & control, Postmenopause, Randomized Controlled Trials as Topic, Receptor, Parathyroid Hormone, Type 1, Risk Reduction Behavior, Spinal Fractures

Dateibeschreibung: application/pdf

Relation: info:eu-repo/semantics/altIdentifier/pmid/37130601; info:eu-repo/semantics/altIdentifier/pissn/0959-8146; info:eu-repo/semantics/altIdentifier/eissn/1756-1833

Verfügbarkeit: https://pure.au.dk/portal/en/publications/835d269b-d8a4-4b11-b8b6-b1ef819f92a8
https://doi.org/10.1136/bmj-2021-068033
https://pure.au.dk/ws/files/405937053/bmj-2021-068033.full.pdf

Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal

Autoren: Harry David True Rupert George Ricks Joel Anthony Smith

Quelle: Drug and Therapeutics Bulletin. 61:61-63

Schlagwörter: calcium and bone, Bone Density Conservation Agents, Diphosphonates, ear, Ear Canal/diagnostic imaging, nose and throat/otolaryngology, 3. Good health, otolaryngology / ENT, Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging/surgery, otitis, Humans, Bisphosphonate-Associated Osteonecrosis of the Jaw, Female, unwanted effects / adverse reactions, Denosumab, Denosumab/adverse effects, Cholesteatoma, Ear Canal, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/34130974
https://pubmed.ncbi.nlm.nih.gov/36008096
https://pubmed.ncbi.nlm.nih.gov/34130974/
https://casereports.bmj.com/content/14/6/e241203
https://europepmc.org/article/MED/34130974
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208004
https://casereports.bmj.com/content/bmjcr/14/6/e241203.full.pdf

A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients

Autoren: Seoyeon Jung Jaeyeon Kim Jin Hoo Park et al.

Weitere Verfasser: Seoyeon Jung Jaeyeon Kim Jin Hoo Park et al.

Quelle: Sci Rep
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)

Schlagwörter: 0301 basic medicine, Bone Density Conservation Agents, Diphosphonates, Osteonecrosis* / chemically induced, Science, Osteonecrosis, Bone Density Conservation Agents / adverse effects, Article, Denosumab* / adverse effects, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Diphosphonates / adverse effects, Osteoporosis* / drug therapy, Medicine, Humans, Osteoporosis, Bisphosphonate-Associated Osteonecrosis of the Jaw, Denosumab, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35606457
https://doaj.org/article/1dafe85ac798454e8523ad0759373ea3

Letter by Spiering et al Regarding Article, 'Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial'

Autoren: Wilko Spiering Willem P. Mali Pim A. de Jong et al.

Weitere Verfasser: Wilko Spiering Willem P. Mali Pim A. de Jong et al.

Quelle: Circulation. 144

Schlagwörter: 03 medical and health sciences, Aortic Valve Stenosis/diagnostic imaging, Letter, 0302 clinical medicine, Alendronate, Double-Blind Method, Physiology (medical), Comment, Humans, Aortic Valve Stenosis, Denosumab, Denosumab/adverse effects, Cardiology and Cardiovascular Medicine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/34843397
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055622
https://dspace.library.uu.nl/handle/1874/444477

Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK: a population-based cohort analysis including over 200,000 participants from Spain and the UK

Autoren: T P van Staa Muhammad Javaid S Khalid et al.

Weitere Verfasser: T P van Staa Muhammad Javaid S Khalid et al.

Quelle: Martín-Merino, E, Petersen, I, Hawley, S, Álvarez-Gutierrez, A, Khalid, S, Llorente-Garcia, A, Delmestri, A, Javaid, M K, Van Staa, T P, Judge, A, Cooper, C & Prieto-Alhambra, D 2018, ' Risk of venous thromboembolism among users of different anti-osteoporosis drugs : a population-based cohort analysis including over 200,000 participants from Spain and the UK ', Osteoporosis International, vol. 29, no. 2, pp. 467–478 . https://doi.org/10.1007/s00198-017-4308-5
Martín-Merino, E, Petersen, I, Hawley, S, Álvarez-Gutierrez, A, Khalid, S, Llorente-Garcia, A, Delmestri, A, Javaid, M K, van Staa, T P, Judge, A, Cooper, C & Prieto-Alhambra, D 2017, 'Risk of venous thromboembolism among users of different anti-osteoporosis drugs : a population-based cohort analysis including over 200,000 participants from Spain and the UK', Osteoporosis International, pp. 1-12. https://doi.org/10.1007/s00198-017-4308-5

Schlagwörter: Male, Thiophenes, Thiophenes/adverse effects, Risk Assessment, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Primary Health Care/methods, Teriparatide/adverse effects, Teriparatide, 80 and over, Anti-osteoporosis medication, Electronic health records, Humans, Bone Density Conservation Agents/adverse effects, Denosumab/adverse effects, Risk Assessment/methods, Aged, Aged, 80 and over, Alendronate, Bone Density Conservation Agents, Diphosphonates, Primary Health Care, United Kingdom/epidemiology, Pharmacoepidemiology, Alendronate/adverse effects, Venous Thromboembolism, Middle Aged, Primary care, 16. Peace & justice, United Kingdom, 3. Good health, Diphosphonates/adverse effects, Spain, Spain/epidemiology, Venous Thromboembolism/chemically induced, Female, Denosumab, Venous thromboembolism

Dateibeschreibung: application/pdf

Zugangs-URL: https://ora.ox.ac.uk/objects/uuid:29f0bf86-f1b6-40dc-af9b-43292de30a8f/download_file?safe_filename=MISS_Clinical%2BPaper_28092017.pdf&file_format=application%2Fpdf&type_of_work=Journal+article
https://pubmed.ncbi.nlm.nih.gov/29199359
https://research-portal.uu.nl/en/publications/bd5352e2-b5de-4588-9ff0-29cf630b607b
https://doi.org/10.1007/s00198-017-4308-5
https://link.springer.com/article/10.1007%2Fs00198-017-4308-5
http://dspace.library.uu.nl/handle/1874/376806
https://www.kennedy.ox.ac.uk/publications/809230
https://ora.ox.ac.uk/objects/pubs:809230
https://research-information.bris.ac.uk/en/publications/risk-of-venous-thromboembolism-among-users-of-different-antiosteoporosis-drugs(96424aca-97f6-4f82-9a2c-17ac31191ef6).html
https://research-information.bris.ac.uk/files/159337243/MISS_Clinical_Paper_28092017.pdf
https://research-information.bris.ac.uk/en/publications/96424aca-97f6-4f82-9a2c-17ac31191ef6
https://hdl.handle.net/1983/96424aca-97f6-4f82-9a2c-17ac31191ef6
https://dspace.library.uu.nl/handle/1874/376806
https://discovery-pp.ucl.ac.uk/id/eprint/10043602/

Prolia® (denosumab) easy to start, but difficult to stop / Prolia® (denosumab) let at starte, men svaert at stoppe

Autoren: Tillingsöe, Hanne Beck Jensen, Jens Erik

Quelle: Månedsskrift for Almen Praksis. 97(2):137

Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics

Autoren: Kang-Hee Lee Wonse Park Tae Min You et al.

Weitere Verfasser: Kang-Hee Lee Wonse Park Tae Min You et al.

Quelle: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 120:548-553

Schlagwörter: Bone Density Conservation Agents, Denosumab/pharmacokinetics, Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnosis, Breast Neoplasms, Middle Aged, 3. Good health, Bisphosphonate-Associated Osteonecrosis of the Jaw/therapy, 03 medical and health sciences, 0302 clinical medicine, Breast Neoplasms/drug therapy, Bone Density Conservation Agents/adverse effects, Humans, Bisphosphonate-Associated Osteonecrosis of the Jaw, Female, Denosumab, Bone Density Conservation Agents/pharmacokinetics, Denosumab/adverse effects

Dateibeschreibung: 548~553

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/26337218
https://mdanderson.elsevierpure.com/en/publications/denosumab-related-osteonecrosis-of-the-jaw-a-case-report-and-mana
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141755
https://www.ncbi.nlm.nih.gov/pubmed/26337218
https://pubmed.ncbi.nlm.nih.gov/26337218/
https://europepmc.org/article/MED/26337218
https://www.sciencedirect.com/science/article/pii/S2212440315010962

Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK

Autoren: Martín-Merino, E Petersen, I Hawley, S et al.

Weitere Verfasser: Martín-Merino, E Petersen, I Hawley, S et al.

Schlagwörter: Aged, 80 and over, Alendronate/adverse effects, Bone Density Conservation Agents/adverse effects, Cohort Studies, Denosumab/adverse effects, Diphosphonates/adverse effects, Female, Humans, Male, Middle Aged, Primary Health Care/methods, Risk Assessment/methods, Spain/epidemiology, Teriparatide/adverse effects, Thiophenes/adverse effects, United Kingdom/epidemiology, Venous Thromboembolism/chemically induced

Dateibeschreibung: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/376806

Verfügbarkeit: https://dspace.library.uu.nl/handle/1874/376806

Effets indésirables des traitements contre l’ostéoporose : comment les expliquer aux patient-e-s ? [Side effects of osteoporosis treatments: how to explain them to patients?]

Autoren: Curraj, E. Gonzalez Rodriguez, E.

Quelle: Revue medicale suisse, vol. 19, no. 823, pp. 746-751

Schlagwörter: Humans, Female, Bone Density Conservation Agents/adverse effects, Denosumab/adverse effects, Osteoporosis/chemically induced, Osteoporosis/drug therapy, Teriparatide/adverse effects, Zoledronic Acid/therapeutic use, Drug-Related Side Effects and Adverse Reactions, Osteoporosis, Postmenopausal/drug therapy, Osteoporotic Fractures, Diphosphonates/adverse effects, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://serval.unil.ch/resource/serval:BIB_0510C417447B.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_0510C417447B3
https://serval.unil.ch/notice/serval:BIB_0510C417447B